Advinus Therapeutics increases Provantis user licenses by 40% at Bangalore facility to support growth in India Operations
CONSHOHOCKEN, PA - (BUSINESS WIRE) -January
27, 2012 - - Instem, a leading provider of early
development software applications, announced today that
Advinus Therapeutics (Advinus) has purchased additional Provantis®
preclinical software user licenses for their 220,000
square foot facility in Bangalore.
Advinus is a research-based Pharmaceutical company offering
end-to-end development services to the global
Pharmaceutical, Agrochemical and Biotech industries, while
at the same time creating long-term value through internal
and collaborative innovative Drug Discovery.
Instem has been proud to support Advinus since 2005 when they selected Instem's integrated Provantis solution suite following a comprehensive competitive evaluation of preclinical systems on the market.
Key facts
- New users to access integrated General Toxicology, Clinical Pathology, Pathology and Protocol & Report Assembly (P&RA) modules deploying at Bangalore facility
- Unique P&RA module provides Advinus faster, more efficient production of study protocols and final reports
- Order represents 40% Increase in User Licenses
Dr. R. S. Rao, Head, Safety Assessment at Advinus comments, "We have been extremely impressed with Instem's products and services as well as the knowledge, commitment and experience of the Instem team. The deployment of Instem solutions at our Bangalore site has been instrumental in helping us to attract more Western business, as well as further enhancing our client services and ensuring GLP compliance."
Demand for regulatory toxicology services has grown within India in recent years, fueled by the internal investments of Indian pharmaceutical and chemical companies, the recent addition of India within the OECD Mutual Acceptance of Data program and the demand from elsewhere in the world for high-quality, cost-effective non-clinical services.
"Our partnership with Advinus has successfully developed over the years and we are delighted that they have committed to further roll out Provantis across their organization," comments Neil Donaldson, Instem's VP of Asian and European Operations. "Given our presence in the region and our commitment to the Indian R&D community, we believe that Instem is ideally poised to support the important role that Indian organizations play in this increasingly competitive global market".
About Advinus Therapeutics
Advinus Therapeutics is a research-based Pharmaceutical
Company founded by leading global pharmaceutical executives
and promoted by the TATA Group. The company is the first of
its kind in India to offer end-to-end development services
to the global Pharmaceutical, Agrochemical and Biotech
industries and at the same time creating long-term value
through internal and collaborative innovative Drug
Discovery.
Advinus has three operational sites; Advinus Drug
Discovery, which is located in a state of the art facility
in Pune (near Mumbai) and the Advinus Pharmaceutical and
Agrochemical development centers based in Bangalore.
Advinus' vision is to emerge as the leading and most
admired life sciences R&D company from India, creating
value for its customers and stakeholders.
About Instem
Instem is a world-leading information solutions
provider to the life sciences - accelerating drug and
chemical development by increasing client productivity and
enhancing the processes that lead to safer, more effective
products. In addition to highly focused departmental and
scientific solutions, Instem provides a range of business
intelligence, planning, workflow management, document
management and report compilation applications.
Instem supports clients around the world through full service offices in the United States, United Kingdom and China. Instem additionally has resource locations in India and a full service distributor based in Japan.
distribué par | Ce noodl a été diffusé par Instem Life Science Systems plc et initialement mise en ligne sur le site http://www.instem.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-27 12:07:00 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |